Tego Science

테고사이언스 · 191420

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$49.1M (₩67.8B)

Overview

Tego Science develops and supplies cell therapy products, treatments that use living cells to address conditions such as burns, foot ulcers, skin wrinkles, and tendon injuries at a biological level.

Its approved products are used in clinical and hospital settings in South Korea, and it also provides contract development, manufacturing, and quality-testing services to other cell-therapy developers. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds multiple cell-therapy approvals from Korea's drug regulator and operates its own GMP-certified manufacturing facility, making contract services a growing part of its business alongside its own products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$4.3M
▼ −12.1% YoY
Operating profit · FY2025
−US$3.2M
Loss widened
Net income · FY2025
−US$5.1M
Turned to loss

Revenue

  • FY2023US$5.6M
  • FY2024US$4.9M
  • FY2025US$4.3M

Operating profit

  • FY2023−US$860.8K
  • FY2024−US$1.6M
  • FY2025−US$3.2M

Net income

  • FY2023−US$1.7M
  • FY2024US$2.4M
  • FY2025−US$5.1M

Key ratios (FY2025)

ROE
-13.9%
Debt/Eq
55.3%
Op. margin
-74.5%
Net margin
-118.2%
Rev. YoY
▼ −12.1%

Why it matters

The company holds regulatory approval for three cell-therapy products covering five indications from Korea's Ministry of Food and Drug Safety, a relatively rare position in the domestic market.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.